Conversational Agent for Cancer
(ECA-PRO Aim 3 Trial)
Trial Summary
What is the purpose of this trial?
Over the past decade, the investigators have developed and tested a toll with the potential to enhance PROs at the individual level- embodied conversational agents (ECA), which are computer characters that simulate face-to-face conversation using voice, hand gestures, gaze cues, and other nonverbal behavior. The investigators have successfully used ECAs in behavioral interventions for populations with limited health literacy, elderly patients, and patients with cancer. Face-to-face encounters, in conjunction with written instructions supported by pictures, remains one of the best methods for communicating information in general but is particularly effective for individuals with limited health literacy. The investigators have also demonstrated that ECAs can be used as valid alternatives to standard paper-based surveys for substance use screening, and that the display of empathy for patients and other relational behavior by ECAs leads to increased engagement by patients over time.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the Embodied Conversational Agent treatment for cancer?
Is the Conversational Agent for Cancer safe for humans?
How is the Embodied Conversational Agent treatment different from other cancer treatments?
The Embodied Conversational Agent is unique because it uses artificial intelligence to simulate human conversation, providing dynamic interaction and support for cancer patients through text or voice on smartphones or computers. Unlike traditional treatments, it focuses on enhancing patient follow-up and potentially reducing emergency visits by offering real-time information and support.1291011
Research Team
Michael Paasche-Orlow, MD, MPH
Principal Investigator
Tufts Medical Center
Eligibility Criteria
This trial is for English or Spanish-speaking adults with cancer who can consent independently, have good hearing and vision (with correction), and are patients of oncologists at Boston Medical Center. There are no specific exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to provide data for 6 weeks using ECA-PRO or standard web administration (REDCap)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Embodied Conversational Agent
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tufts Medical Center
Lead Sponsor
Boston Medical Center
Collaborator